"Mesothelioma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)
| Descriptor ID |
D008654
|
| MeSH Number(s) |
C04.557.470.035.510 C04.557.470.660.510
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mesothelioma".
Below are MeSH descriptors whose meaning is more specific than "Mesothelioma".
This graph shows the total number of publications written about "Mesothelioma" by people in this website by year, and whether "Mesothelioma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 3 | 0 | 3 |
| 1999 | 2 | 0 | 2 |
| 2000 | 2 | 0 | 2 |
| 2001 | 3 | 0 | 3 |
| 2002 | 4 | 0 | 4 |
| 2003 | 1 | 0 | 1 |
| 2004 | 6 | 2 | 8 |
| 2005 | 7 | 0 | 7 |
| 2006 | 5 | 1 | 6 |
| 2007 | 3 | 0 | 3 |
| 2008 | 7 | 1 | 8 |
| 2009 | 7 | 0 | 7 |
| 2010 | 5 | 2 | 7 |
| 2011 | 8 | 1 | 9 |
| 2012 | 13 | 0 | 13 |
| 2013 | 10 | 1 | 11 |
| 2014 | 7 | 1 | 8 |
| 2015 | 11 | 0 | 11 |
| 2016 | 15 | 0 | 15 |
| 2017 | 6 | 1 | 7 |
| 2018 | 16 | 1 | 17 |
| 2019 | 11 | 0 | 11 |
| 2020 | 1 | 0 | 1 |
| 2021 | 4 | 0 | 4 |
| 2022 | 5 | 0 | 5 |
| 2023 | 5 | 0 | 5 |
| 2024 | 15 | 0 | 15 |
| 2025 | 6 | 0 | 6 |
| 2026 | 5 | 0 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mesothelioma" by people in Profiles.
-
Mesothelioma: Pleural, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2026 Aug; 24(8).
-
Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study. Lancet Oncol. 2026 Jul; 27(7):879-892.
-
The Society of Thoracic Surgeons 2026 Expert Consensus on the Multimodal Treatment of Pleural Mesothelioma. Ann Thorac Surg. 2026 07; 122(1):3-21.
-
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Impact of Common Molecular Alterations and Programmed Death-Ligand 1 Expression on Overall Survival in a Select Cohort From the International Association for the Study of Lung Cancer Ninth Edition Staging Database. J Thorac Oncol. 2026 Jul; 21(7):103681.
-
Germline genetic testing and privacy concerns in patients with mesothelioma. Genet Med. 2026 05; 28(5):102550.
-
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial. Nat Med. 2025 Dec; 31(12):4281-4290.
-
Consensus guideline for the management of peritoneal mesothelioma. Cancer. 2025 Jul 01; 131(13):e35868.
-
Clinical and Pathologic Phenotyping of Mesotheliomas Developing in Carriers of Germline BAP1 Mutations. J Thorac Oncol. 2025 11; 20(11):1683-1698.
-
Consensus Guideline for the Management of Peritoneal Mesothelioma. Ann Surg Oncol. 2026 Jun; 33(6):5125-5141.
-
Immune Composition and Immunotherapy Outcomes of Mesothelioma With BAP1, CDKN2A, MTAP, and NF2 Alterations. J Thorac Oncol. 2025 11; 20(11):1615-1625.